-
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK Target Oncol. (IF 5.4) Pub Date : 2024-03-16 Rachael Batteson, Emma Hook, Hollie Wheat, Anthony J. Hatswell, Helene Vioix, Thomas McLean, Stamatia Theodora Alexopoulos, Shobhit Baijal, Paul K. Paik
-
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients Target Oncol. (IF 5.4) Pub Date : 2024-03-11 Keisuke Onoi, Tadaaki Yamada, Kenji Morimoto, Hayato Kawachi, Rei Tsutsumi, Takayuki Takeda, Asuka Okada, Nobuyo Tamiya, Yusuke Chihara, Shinsuke Shiotsu, Yoshizumi Takemura, Takahiro Yamada, Isao Hasegawa, Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama
-
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC Target Oncol. (IF 5.4) Pub Date : 2024-03-11 Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lu, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz Kowalski, Laura Bonanno, Manuel Dómine, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi-Long Wu
-
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review Target Oncol. (IF 5.4) Pub Date : 2024-03-11 Patrick Crotty, Karim Kari, Griffin K. Hughes, Chase Ladd, Ryan McIntire, Brooke Gardner, Andriana M. Peña, Sydney Ferrell, Jordan Tuia, Jacob Cohn, Alyson Haslam, Vinay Prasad, Matt Vassar
-
Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia Target Oncol. (IF 5.4) Pub Date : 2024-03-11 Dian Jin, Haoguang Chen, Jingsong He, Yi Li, Gaofeng Zheng, Yang Yang, Yi Zhao, Jing Le, Wenxiu Shu, Donghua He, Zhen Cai
-
Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia—A Podcast Target Oncol. (IF 5.4) Pub Date : 2024-03-08
Abstract Older patients with acute lymphoblastic leukemia (ALL) have historically had poor outcomes (5-year survival rate, 20%) with standard intensive and dose-adjusted chemotherapy regimens, due to a high incidence of adverse biologic features including high-risk cytogenetics, presence of TP53 mutations, and poor tolerance to intensive therapy. Thus, there is an unmet medical need in this patient
-
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer Target Oncol. (IF 5.4) Pub Date : 2024-03-06
Abstract Sacituzumab govitecan (TRODELVY®) is a first-in-class trophoblast cell-surface antigen 2 (Trop-2)–directed antibody and topoisomerase I inhibitor conjugate that is approved globally as monotherapy for the treatment of adults with unresectable locally advanced or metastatic, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−; defined as immunohistochemistry
-
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G Target Oncol. (IF 5.4) Pub Date : 2024-03-01 Toshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, Toshiki Masuishi, Yasushi Tsuji, Hirokazu Shoji, Kenro Hirata, Takao Tsuduki, Akitaka Makiyama, Naoki Izawa, Naoki Takahashi, Masahiro Tsuda, Hisateru Yasui, Takashi Ohta, Yosuke Kito, Satoshi Otsu, Shuichi Hironaka, Kentaro Yamazaki, Narikazu Boku, Ichinosuke Hyodo, Kenichi Yoshimura, Kei Muro
-
EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation Target Oncol. (IF 5.4) Pub Date : 2024-02-28
Abstract Background Data from studies looking at both EGFR and ERBB2 exon 20 insertion mutations (-20ins) in the same cohort of patients with non-small cell lung cancer (NSCLC) are limited. Objective The purpose of this study was to analyze EGFR/ERBB2-20ins in all-stage NSCLC patients to reveal their histological and molecular features, and to retrospectively evaluate the results of first-line real-world
-
Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study Target Oncol. (IF 5.4) Pub Date : 2024-02-28 Gwan Hee Han, Hae-Rim Kim, Hee Yun, Jae-Hoon Kim, Hanbyoul Cho
-
Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data Target Oncol. (IF 5.4) Pub Date : 2024-02-28 Alexander Olkus, Aurelie Tomczak, Anne Katrin Berger, Conrad Rauber, Philip Puchas, Cyrill Wehling, Thomas Longerich, Arianeb Mehrabi, De-Hua Chang, Jakob Liermann, Sophia Schäfer, Jan Pfeiffenberger, Dirk Jäger, Patrick Michl, Christoph Springfeld, Michael T. Dill
-
Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review Target Oncol. (IF 5.4) Pub Date : 2024-02-24 Urszula Żebrowska, Walentyna Balwierz, Jarosław Wechowski, Aleksandra Wieczorek
-
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma Target Oncol. (IF 5.4) Pub Date : 2024-02-24 Julia Maria Ressler, Erwin Tomasich, Teresa Hatziioannou, Helmut Ringl, Gerwin Heller, Rita Silmbrod, Lynn Gottmann, Angelika Martina Starzer, Nina Zila, Philipp Tschandl, Christoph Hoeller, Matthias Preusser, Anna Sophie Berghoff
-
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab Target Oncol. (IF 5.4) Pub Date : 2024-02-12 Margherita Rimini, Eleonora Loi, Mario Domenico Rizzato, Tiziana Pressiani, Caterina Vivaldi, Eleonora Gusmaroli, Lorenzo Antonuzzo, Erika Martinelli, Ingrid Garajova, Guido Giordano, Jessica Lucchetti, Marta Schirripa, Noemi Cornara, Federico Rossari, Francesco Vitiello, Elisabeth Amadeo, Mara Persano, Vittoria Matilde Piva, Rita Balsano, Francesca Salani, Chiara Pircher, Stefano Cascinu, Monica Niger
-
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy Target Oncol. (IF 5.4) Pub Date : 2024-02-03 Tomas Buchler, Alexandr Poprach
Several regimens combining immunotherapy and tyrosine kinase inhibitors (TKIs) have recently been validated for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). While immunotherapy is typically discontinued after 2 years in patients who neither progress nor experience limiting toxicity, according to the protocols of most recent phase III clinical trials, TKIs are to
-
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies Target Oncol. (IF 5.4) Pub Date : 2024-01-30
Abstract Background Immunotherapy has revolutionized the treatment of hepatocellular carcinoma (HCC). However, whether adding immunotherapy to antiangiogenic therapy benefits patients with unresectable HCC (uHCC) more in the first-line setting remains controversial. Objective In this analysis, we compared the clinical outcomes of lenvatinib monotherapy with atezolizumab plus bevacizumab combination
-
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08) Target Oncol. (IF 5.4) Pub Date : 2024-01-29 Hung-Ming Wang, Pei-Jen Lou, Muh-Hwa Yang, Tein-Hua Chen, Ming-Yu Lien, Jin-Ching Lin, Jo-Pai Chen, Wei-Chen Lu, Hsueh-Ju Lu, Tai-Lin Huang, Chia-Jui Yen, Shang-Yin Wu, Hui-Ching Wang, Meng-Che Hsieh
-
Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China Target Oncol. (IF 5.4) Pub Date : 2024-01-24
Abstract Background The prognostic impact of HER2-low on overall survival (OS) and disease-free survival (DFS) in patients with resectable breast cancer (BC) remains controversial, partly resulting from the hormone receptor (HR) status. Objective To investigate the prognostic impact of HER2-low in different HR subgroups. Patients and Methods We retrospectively retrieved medical records of treatment-naive
-
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma Target Oncol. (IF 5.4) Pub Date : 2024-01-22 Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Francesca Salani, Mariarosaria Marseglia, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo
-
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma Target Oncol. (IF 5.4) Pub Date : 2024-01-18
Abstract Tremelimumab (tremelimumab-actl; Imjudo®) is a monoclonal antibody and immune checkpoint inhibitor (ICI) that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). A single, priming dose of intravenous tremelimumab is used in combination with durvalumab, an ICI that blocks programmed cell-death ligand 1, in a regimen known as STRIDE (Single Tremelimumab Regular Interval Durvalumab)
-
Pemigatinib: A Review in Advanced Cholangiocarcinoma Target Oncol. (IF 5.4) Pub Date : 2024-01-11 James E. Frampton
-
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer Target Oncol. (IF 5.4) Pub Date : 2024-01-09 Yu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, Tetsuji Terazawa, Hisato Kawakami, Mitsuru Yokota, Masato Nakamura, Masahito Kotaka, Naotoshi Sugimoto, Hitoshi Ojima, Eiji Oki, Takeshi Kajiwara, Yoshiyuki Yamamoto, Yasushi Tsuji, Tadamichi Denda, Takao Tamura, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Satoshi Morita, Kuniaki Shirao, Naruhito Takenaka, Daisuke Ozawa, Takayuki Yoshino
-
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma Target Oncol. (IF 5.4) Pub Date : 2023-12-22
Abstract Background Palmitoyl-protein thioesterase-1 (PPT1) is a clinical stage druggable target for inhibiting autophagy in cancer. Objective We aimed to determine the cellular and molecular activity of targeting PPT1 using ezurpimtrostat, in combination with an anti-PD-1 antibody. Methods In this study we used a transgenic immunocompetent mouse model of hepatocellular carcinoma. Results Herein, we
-
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea Target Oncol. (IF 5.4) Pub Date : 2023-12-18 Yeokyeong Shin, Bo Hyun Moon, Baek-Yeol Ryoo, Heung-Moon Chang, Kyu-pyo Kim, Yong Sang Hong, Tae Won Kim, Jin-Sook Ryu, Yong-il Kim, Changhoon Yoo
-
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors Target Oncol. (IF 5.4) Pub Date : 2023-12-08 Serafina Martella, Marco Maria Aiello, Valentina Bertaglia, Riccardo Cau, Nerina Denaro, Andrea Cadoni, Silvia Novello, Mario Scartozzi, Giuseppe Novello, Hector Josè Soto Parra, Luca Saba, Cinzia Solinas, Michele Porcu
-
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis Target Oncol. (IF 5.4) Pub Date : 2023-12-02 Ming-Yu Lien, Tzer-Zen Hwang, Chih-Chun Wang, Ching-Yun Hsieh, Chuan-Chien Yang, Chien-Chung Wang, Ching-Feng Lien, Yu-Chen Shih, Shyh-An Yeh, Meng-Che Hsieh
-
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer. Target Oncol. (IF 5.4) Pub Date : 2023-11-29 Simon Fung,Yahiya Y Syed
-
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis Target Oncol. (IF 5.4) Pub Date : 2023-11-22 Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, Evaristo Maiello, Giuseppe Procopio, Vincenza Conteduca, Massimo Di Maio
-
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma Target Oncol. (IF 5.4) Pub Date : 2023-11-13 Alexandr Poprach, Igor Kiss, Michal Stanik, Tamara Barusova, Lenka Pospisilova, Ondrej Fiala, Jindrich Kopecky, Igor Richter, Bohuslav Melichar, Hana Studentova, Radek Lakomy, Milos Holanek, Aneta Rozsypalova, Anezka Zemanková, Marek Svoboda, Tomas Buchler
-
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study) Target Oncol. (IF 5.4) Pub Date : 2023-11-15 Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, Hélène Doubre, Chantal Decroisette, Pierre Demontrond, Gwenaelle Le Garff, Lionel Falchero, Eric Huchot, Sabine Vieillot, Romain Corre, Laure Kazulinski, Acya Bizieux, Laurence Bigay-Gamé, Hugues Morel, Olivier Molinier, Christos Chouaïd, Florian Guisier
-
Durvalumab: A Review in Advanced Biliary Tract Cancer Target Oncol. (IF 5.4) Pub Date : 2023-11-09 Simon Fung, Yahiya Y. Syed
-
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer Target Oncol. (IF 5.4) Pub Date : 2023-11-06 Lauren C. Bylsma, Xerxes Pundole, Chia-Hsin Ju, Naushin Hooda, Naimisha Movva, Ehab Elkhouly, Gwyn Bebb, Jon Fryzek, Pablo Martinez, Akhila Balasubramanian, Anne-Marie C. Dingemans
-
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers Target Oncol. (IF 5.4) Pub Date : 2023-11-03 Marine Marchal, Vincent Leroy, Hélène Behal, Eric Dansin, Nicolas Paris, Soraya Bordier, Sarah Humez, Fabienne Escande, Clément Gauvain, Alexis B. Cortot
-
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status Target Oncol. (IF 5.4) Pub Date : 2023-10-30 Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Naoya Nishioka, Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
-
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Target Oncol. (IF 5.4) Pub Date : 2023-10-25 Albiruni R. Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, Myung-Ju Ahn, Pamela Munster, George Blumenschein, Benjamin Solomon, Darren Wan-Teck Lim, Ruey-Long Hong, David Pfister, Nabil F. Saba, Se-Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean-Pierre Delord
-
Ivosidenib: A Review in Advanced Cholangiocarcinoma Target Oncol. (IF 5.4) Pub Date : 2023-10-19 James E. Frampton
-
Back to the Bench: Unveiling the Tissue Context is Crucial to Enhance the Efficacy of Agnostic Therapies in Oncology. Target Oncol. (IF 5.4) Pub Date : 2023-10-21 Alessandro Ottaiano,Francesco Sabbatino,Francesco Perri,Marco Cascella,Mariachiara Santorsola,Guglielmo Nasti
-
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators Target Oncol. (IF 5.4) Pub Date : 2023-10-19 Francesco Volta, Silvia La Monica, Alessandro Leonetti, Letizia Gnetti, Mara Bonelli, Andrea Cavazzoni, Claudia Fumarola, Maricla Galetti, Kamal Eltayeb, Roberta Minari, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
-
Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma Target Oncol. (IF 5.4) Pub Date : 2023-10-19 Ning Wang, Zhenxian Mo, Lu Pan, Minhua Zhou, Xiaolan Ye, Xinjian Liu, Xiong Cai, Changgeng Qian, Feili Chen, Yan Xiong, Fushun Fan, Wenyu Li
-
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China Target Oncol. (IF 5.4) Pub Date : 2023-10-17 Minmin Zhao, Shanhu Qiu, Xin Wu, Pengcheng Miao, Zhi Jiang, Tao Zhu, Xizhong Xu, Yanling Zhu, Bei Zhang, Donglan Yuan, Yang Zhang, Wei Sun, Aiqin He, Min Zhao, Wenjie Hou, Yingli Zhang, Zhuyan Shao, Meiqun Jia, Mei Li, Jun Chen, Jingcheng Xu, Bingwei Chen, Ying Zhou, Yang Shen
-
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast Target Oncol. (IF 5.4) Pub Date : 2023-10-04 Xiuning Le, Eric Nadler, Daniel B. Costa, John Victor Heymach
-
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma Target Oncol. (IF 5.4) Pub Date : 2023-10-03 Connie Kang
-
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience Target Oncol. (IF 5.4) Pub Date : 2023-09-25 Danilo De Novellis, Raffaele Fontana, Salvatore Palmieri, Roberta Della Pepa, Maria Di Perna, Giusy Cetani, Daniela Esposito, Angela Amendola, Giuseppe Delle Cave, Bianca Serio, Denise Morini, Michela Rizzo, Laura Mettivier, Fabio Trastulli, Stefano Rocco, Anastasia Pagano, Serafina Barbato, Aldo Leone, Martina La Magna, Rosario Bianco, Gabriella Rascato, Angela Carobene, Bianca Cuffa, Marialuigia
Background Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or at a subcutaneous fixed dose of 1800 mg. However, the subcutaneous formulation has only recently been approved in Europe, and real-life data on its safety are still few. Objective In this multicenter retrospective real-life experience
-
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer Target Oncol. (IF 5.4) Pub Date : 2023-09-26 Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
-
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences Target Oncol. (IF 5.4) Pub Date : 2023-09-20 Jacqueline C. Barrientos, Ayed O. Ayed, Agnes Cha, Senxi Du, Bruno Fang, Ryan Hall, Stanley M. Marks, Eileen Peng, Joanna M. Rhodes, Kellie Ryan, Sharon B. Winters, Percy L. Yeung, Jing-Zhou Hou
-
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1 Target Oncol. (IF 5.4) Pub Date : 2023-09-15 Xin Miao, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa M. Uhlar, Arnob Banerjee, Jenna D. Goldberg, Danielle Trancucci, Amit Apte, Raluca Verona, Lixia Pei, Rachit Desai, Kathleen Hickey, Yaming Su, Daniele Ouellet, Mahesh N. Samtani, Yue Guo, Alfred L. Garfall, Amrita Krishnan, Saad Z. Usmani, Honghui Zhou, Suzette Girgis
-
Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer Target Oncol. (IF 5.4) Pub Date : 2023-09-08 Amandine Gouverneur, Clélia Favary, Jérémy Jové, Magali Rouyer, Emmanuelle Bignon, Francesco Salvo, Achille Tchalla, Elena Paillaud, Thomas Aparicio, Pernelle Noize
-
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients Target Oncol. (IF 5.4) Pub Date : 2023-09-08 Scott Jew, Sean Bujarski, Bernard Regidor, Marsiye Emamy-Sadr, Regina Swift, Benjamin Eades, Susanna Kim, Shahrooz Eshaghian, James R. Berenson
-
Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma Target Oncol. (IF 5.4) Pub Date : 2023-09-04 Jiayu Wang, Dana Al-Majid, J. Chad Brenner, Joshua D. Smith
-
Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study Target Oncol. (IF 5.4) Pub Date : 2023-09-05 Seiichiro Mitani, Yosuke Kito, Kaori Hino, Kentaro Kawakami, Naoki Izawa, Fumiyasu Hanamura, Yoshiyuki Yamamoto, Hirokazu Shoji, Azusa Komori, Shogen Boku, Kenji Tsuchihashi, Kyoko Kato, Yoshikane Nonagase, Toshihiko Matsumoto, Mitsuhiro Furuta, Hisato Kawakami
-
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis Target Oncol. (IF 5.4) Pub Date : 2023-09-01 Devon J. Boyne, David E. Dawe, Huma Shakir, Ofodile Joe-Uzuegbu, Eliya Farah, Aliyah Pabani, Cristina Baratta, Darren R. Brenner, Winson Y. Cheung
-
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial Target Oncol. (IF 5.4) Pub Date : 2023-09-02 Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean-Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vázquez Estévez, Burcin Simsek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex
This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was
-
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Target Oncol. (IF 5.4) Pub Date : 2023-08-26 Lan-Hsi Lin, Mohammad Ghasemi, Sarah M. Burke, Cory K. Mavis, Jenna R. Nichols, Pallawi Torka, Donald E. Mager, Francisco J. Hernandez-Ilizaliturri, Andrew K. L. Goey
-
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study Target Oncol. (IF 5.4) Pub Date : 2023-08-23 Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date, Nobuyo Tamiya, Yasuhiro Goto, Hibiki Kanda, Yusuke Chihara, Yusuke Kunimatsu, Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama
-
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich Target Oncol. (IF 5.4) Pub Date : 2023-08-18 Danmei Zhang, Klara Dorman, Kathrin Heinrich, Lena Weiss, Myrto Boukovala, Michael Haas, Philipp A. Greif, Frank Ziemann, Georg Beyer, Daniel Roessler, Elisabetta Goni, Bernhard Renz, Jan G. D’Haese, Wolfgang G. Kunz, Max Seidensticker, Stefanie Corradini, Maximilian Niyazi, Steffen Ormanns, Jörg Kumbrink, Andreas Jung, Andreas Mock, Martina Rudelius, Frederick Klauschen, Jens Werner, Julia Mayerle
-
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer Target Oncol. (IF 5.4) Pub Date : 2023-08-05 Arnold Lee
-
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6) Target Oncol. (IF 5.4) Pub Date : 2023-07-24 Hanno M. Witte, Jörg Riedl, Axel Künstner, Anke Fähnrich, Julius Ketzer, Stephanie M. J. Fliedner, Niklas Reimer, Veronica Bernard, Nikolas von Bubnoff, Hartmut Merz, Hauke Busch, Alfred Feller, Niklas Gebauer
-
FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications Target Oncol. (IF 5.4) Pub Date : 2023-07-21 Marjorie E. Zettler
-
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer Target Oncol. (IF 5.4) Pub Date : 2023-07-10 Angela DeMichele, Nicholas Robert, Connie Chen, Sindy Kim, Zhe Zhang, Dongrui Ray Lu, Kathleen M. Aguilar, Yunfei Wang, Benjamin Li, Sebastian Schneeweiss, Jeremy A. Rassen, Michael Gaffney, Lynn McRoy
-
Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study Target Oncol. (IF 5.4) Pub Date : 2023-06-26 Erica M. Storm, Dimitrios Makrakis, Genevieve I. Lin, Rafee Talukder, Dimitra R. Bakaloudi, Eshana E. Shah, Iris W. Liou, David Hockenbery, Petros Grivas, Ali Raza Khaki